去细胞主动脉同种移植物五年结果:ARISE研究及注册数据
ARISE研究为前瞻性单臂多中心试验,评估非冷冻保存去细胞主动脉同种移植物用于主动脉瓣置换。144例患者中位年龄30.4岁,随访中位5.9年,5年免于死亡/再手术/心内膜炎/出血/血栓栓塞分别为97.9%/93.5%/96.4%/99.2%/99.3%,峰值压差中位11.0 mmHg,反流中位0.5级,显示该移植物安全且血流动力学优良。
要点
- ARISE试验纳入144例患者,中位年龄30.4岁,45%有既往心脏手术史。
- 随访中位5.9年,5年免于死亡、再手术、心内膜炎分别为97.9%、93.5%、96.4%。
- 主要疗效终点峰值压差中位11.0 mmHg,反流中位0.5级(0-3级)。
核心结论
- ARISE试验5年结果继续显示去细胞主动脉同种移植物用于主动脉瓣置换安全且血流动力学优良。
研究设计与样本
- 前瞻性、欧盟资助、单臂、多中心研究,在8个中心评估非冷冻保存去细胞主动脉同种移植物用于主动脉瓣置换。
主要发现
- 2015年10月至2018年10月前瞻性纳入144例患者(99例男性),中位年龄30.4岁(IQR 15.9-55.1),45%有既往心脏手术史,19%有2次或以上既往手术。
- 植入去细胞主动脉同种移植物平均直径22.6 mm(SD 2.4),中位手术时间312 min(IQR 234-417),中位体外循环时间154 min(IQR 118-212),中位主动脉阻断时间121 min(IQR 93-150)。
- 术后无需要旁路移植或肾脏替代治疗;发生2例早期死亡(1例术后第3天因左冠状动脉血栓,1例术后5小时因室性心律失常),3例晚期死亡(1例术后4个月因心内膜炎,2例分别于5年和7年后因癌症和韦格纳肉芽肿病无关死亡),总死亡率3.47%。
- 中位随访5.9年(IQR 5.1-6.4,平均5.5年,SD 1.3,最长7.6年),主要疗效终点峰值压差中位11.0 mmHg(IQR 7.8-17.6),反流中位0.5级(IQR 0-0.5,0-3级)。
- 5年免于死亡/再手术/心内膜炎/出血/血栓栓塞分别为97.9%/93.5%/96.4%/99.2%/99.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Decellularized aortic homografts (DAH) were introduced as a new option for aortic valve replacement for young patients. METHODS: A prospective, EU-funded, single-arm, multicentre study in 8 centres evaluating non-cryopreserved DAH for aortic valve replacement. RESULTS: A total of 144 patients (99 male) were prospectively enrolled in the ARISE Trial between October 2015 and October 2018 with a median age of 30.4 years [interquartile range (IQR) 15.9-55.1]; 45% had undergone previous cardiac operations, with 19% having 2 or more previous procedures. The mean implanted DAH diameter was 22.6 mm (standard deviation 2.4). The median operation duration was 312 min (IQR 234-417), the median cardiopulmonary bypass time was 154 min (IQR 118-212) and the median cross-clamp time 121 min (IQR 93-150). No postoperative bypass grafting or renal replacement therapy were required. Two early deaths occurred, 1 due to a LCA thrombus on day 3 and 1 due ventricular arrhythmia 5 h postoperation. There were 3 late deaths, 1 death due to endocarditis 4 months postoperatively and 2 unrelated deaths after 5 and 7 years due to cancer and Morbus Wegener resulting in a total mortality of 3.47%. After a median follow-up of 5.9 years [IQR 5.1-6.4, mean 5.5 years. (standard deviation 1.3) max. 7.6 years], the primary efficacy end-points peak gradient with median 11.0 mmHg (IQR 7.8-17.6) and regurgitation of median 0.5 (IQR 0-0.5) of grade 0-3 were excellent. At 5 years, freedom from death/reoperation/endocarditis/bleeding/thromboembolism were 97.9%/93.5%/96.4%/99.2%/99.3%, respectively. CONCLUSIONS: The 5-year results of the prospective multicentre ARISE trial continue to show DAH to be safe for aortic valve replacement with excellent haemodynamics.
引用
- Horke A, Tudorache I, Laufer G, et al. Five-year results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement-the ARISE Study and ARISE Registry Data. Eur J Cardiothorac Surg. 2024. PMID: 38532304. doi:10.1093/ejcts/ezae121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。